G40.8 G40.2
Conditions
Interventions
Group 1: Data from patients treated with cenobamate with regard to frequency of seizure attack, demographic data, data on side effects, plasma concentration of the anticonvulsant and other known covar
Sponsors
Epilepsiezentrum Kork
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Treatment with cenobamate
Exclusion criteria
Exclusion criteria: 1. Change in cenobamate dose within 7 days prior to determination of cenobamate serum concentration 2. Change in concomitant medication within 7 days prior to determination of serum cenobmate concentration 3. Inadequate documentation of seizure situation and tolerability 4. Non-epileptic seizures 5. Status epilepticus within the last 3 months 6. Data is NOT collected from the following patients: minors, the mentally handicapped, people with dementia, pregnant women, breastfeeding women or emergency patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum concentration of cenobamate which reduces the seizure attack by at least 50% over a period of at least 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum concentration of cenobamate which lead to a documentation of the two most common neurotoxic side effects, which are fatigue and / or dizziness | — |
Countries
Germany
Contacts
Public ContactBernhard Steinhoff
Epilepsiezentrum Kork
Outcome results
None listed